Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy - PubMed (original) (raw)

. 2017 Jan;32(1):108-114.

doi: 10.1002/mds.26813. Epub 2016 Oct 6.

Affiliations

Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy

Ruben Smith et al. Mov Disord. 2017 Jan.

Abstract

Background: Progressive supranuclear palsy (PSP) is difficult to diagnose accurately. The recently developed tau PET tracers may improve the diagnostic work-up of PSP.

Methods: Regional tau accumulation was studied using 18 F-AV-1451 PET in 11 patients with PSP and 11 age-matched healthy controls in the Swedish BioFinder study.

Results: 18 F-AV-1451 standard uptake volume ratios were significantly higher in the basal ganglia in PSP patients when compared with controls (globus pallidus 1.75 vs 1.50; putamen 1.51 vs 1.35). Retention in the basal ganglia was correlated with age in both groups (r = .43-.78, P < .05). In PSP, we observed a significant correlation between clinical deterioration measured with the PSP rating scale and standard uptake volume ratios in the globus pallidus (r = .74, P < .05). However, no 18 F-AV-1451 retention was observed in the cerebral cortex or white matter of either PSP patients or controls, and autoradiography did not reveal any specific binding of AV-1451 to PSP tau aggregates.

Conclusion: We found higher 18 F-AV-1451 retention in the basal ganglia of PSP patients when compared with healthy elderly controls, but also increases with age in both controls and patients. As a result of the overlap in retention between diagnostic groups and the age-dependent increase present also in controls, 18 F-AV-1451 PET might not reliably distinguish individual patients with PSP from controls. However, further studies are needed to evaluate whether 18 F-AV-1451 PET might be useful as a progression marker in clinical PSP trials. © The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Keywords: Progressive supranuclear palsy; basal ganglia; positron emission tomography; tau.

© 2016 International Parkinson and Movement Disorder Society.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Tau standardized uptake value ratios (SUVRs) and correlation to age. A: Averaged 18F‐AV‐1451 images over 80 to 120 minutes in 2 control patients (I and II) and 2 PSP patients (III and IV), aged I = 62, II = 70, III = 73, and IV = 81 years. Scale bar denoting SUVR‐values. B‐D: SUVRs plotted against age in the globus pallidus (B), putamen (C), and thalamus (D). E: Correlation of SUVR values in the globus pallidus plotted against results using the PSP rating scale. F: Statistically significant clusters (P < .001, uncorrected, k > 50 voxels) resulting from a voxelwise t test between AV‐1451 mean images of PSP patients and controls projected on the MNI152 2‐mm brain template. GP, globus pallidus; PSPRS, PSP rating scale. [Color figure can be viewed at

http://wileyonlinelibrary.com

]

Similar articles

Cited by

References

    1. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333–359. - PubMed
    1. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009;8(3):270–279. - PubMed
    1. Arai T, Ikeda K, Akiyama H, et al. Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol 2001;101(2):167–173. - PubMed
    1. Majounie E, Cross W, Newsway V, et al. Variation in tau isoform expression in different brain regions and disease states. Neurobiol Aging 2013;34(7):1922.e7–1922.e12. - PMC - PubMed
    1. Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 2014;29(14):1758–1766. - PubMed

MeSH terms

Substances

LinkOut - more resources